DECORTI, GIULIANA
 Distribuzione geografica
Continente #
NA - Nord America 20.422
EU - Europa 11.248
AS - Asia 9.486
SA - Sud America 1.191
AF - Africa 358
OC - Oceania 40
Continente sconosciuto - Info sul continente non disponibili 10
Totale 42.755
Nazione #
US - Stati Uniti d'America 20.157
SG - Singapore 3.658
PL - Polonia 2.738
CN - Cina 2.118
IT - Italia 2.009
SE - Svezia 1.286
VN - Vietnam 1.106
UA - Ucraina 978
BR - Brasile 910
HK - Hong Kong 908
DE - Germania 827
FI - Finlandia 634
FR - Francia 569
GB - Regno Unito 528
KR - Corea 443
RU - Federazione Russa 414
TR - Turchia 307
NL - Olanda 295
IE - Irlanda 250
IN - India 228
BG - Bulgaria 221
JP - Giappone 122
CA - Canada 117
MA - Marocco 106
AR - Argentina 100
MX - Messico 92
BE - Belgio 83
BD - Bangladesh 80
IQ - Iraq 71
ES - Italia 69
PK - Pakistan 63
ZA - Sudafrica 58
AT - Austria 56
SN - Senegal 54
CH - Svizzera 51
ID - Indonesia 47
CZ - Repubblica Ceca 46
EC - Ecuador 39
SA - Arabia Saudita 39
PH - Filippine 35
TH - Thailandia 34
AU - Australia 33
EG - Egitto 32
CL - Cile 31
CO - Colombia 31
TN - Tunisia 31
UZ - Uzbekistan 28
VE - Venezuela 26
AE - Emirati Arabi Uniti 22
PE - Perù 22
PT - Portogallo 21
JO - Giordania 20
RO - Romania 19
GR - Grecia 18
AZ - Azerbaigian 17
IL - Israele 17
KE - Kenya 17
MY - Malesia 17
PY - Paraguay 17
SI - Slovenia 16
TW - Taiwan 16
RS - Serbia 15
DZ - Algeria 14
DK - Danimarca 13
IR - Iran 12
LT - Lituania 11
NO - Norvegia 10
MD - Moldavia 9
NP - Nepal 9
AL - Albania 8
EU - Europa 8
JM - Giamaica 8
KW - Kuwait 8
NG - Nigeria 8
PA - Panama 8
UY - Uruguay 8
ET - Etiopia 7
HR - Croazia 7
LB - Libano 7
BA - Bosnia-Erzegovina 6
BO - Bolivia 6
CR - Costa Rica 6
DO - Repubblica Dominicana 6
EE - Estonia 6
HU - Ungheria 6
KZ - Kazakistan 6
LK - Sri Lanka 6
LV - Lettonia 6
NZ - Nuova Zelanda 6
TT - Trinidad e Tobago 6
BY - Bielorussia 5
GA - Gabon 5
KG - Kirghizistan 5
LU - Lussemburgo 5
SK - Slovacchia (Repubblica Slovacca) 5
CI - Costa d'Avorio 4
GE - Georgia 4
GT - Guatemala 4
HN - Honduras 4
MN - Mongolia 4
Totale 42.678
Città #
Warsaw 2.477
Singapore 2.212
Woodbridge 2.164
Ashburn 2.008
Ann Arbor 1.851
Fairfield 1.848
Houston 1.351
Chandler 1.315
San Jose 967
Wilmington 886
Hong Kong 878
Jacksonville 851
Seattle 819
Trieste 680
Cambridge 590
Beijing 471
Seoul 418
Princeton 392
Hefei 376
Boardman 365
Munich 338
Ho Chi Minh City 326
Hanoi 277
Chicago 272
Helsinki 270
Los Angeles 262
Dublin 229
Izmir 227
Sofia 220
Lauterbourg 219
Columbus 209
Zgierz 200
Moscow 194
Dallas 183
London 172
Santa Clara 155
The Dalles 151
Frankfurt am Main 144
Council Bluffs 142
Dearborn 131
Buffalo 128
Milan 128
São Paulo 107
New York 105
San Diego 92
Düsseldorf 91
Casablanca 87
Brussels 78
Tokyo 74
Rome 68
Shanghai 63
Orem 59
Dakar 54
Des Moines 49
Redondo Beach 48
Da Nang 45
Phoenix 45
Turku 45
Falls Church 42
Guangzhou 42
Amsterdam 41
Haiphong 41
Denver 40
Chennai 39
Manchester 39
Montreal 39
Brno 37
Nuremberg 37
Atlanta 36
Dong Ket 36
Johannesburg 36
Nanjing 36
Vienna 36
Wroclaw 36
Stockholm 35
Bern 34
Mumbai 34
Tianjin 34
Bremen 33
Washington 33
Brooklyn 32
Redwood City 32
Jinan 31
Lappeenranta 30
Baghdad 28
Curitiba 28
Tashkent 27
Toronto 27
Rio de Janeiro 25
Kunming 24
Shenyang 24
Fremont 23
Norwalk 23
Paris 23
Istanbul 22
Poplar 22
Portsmouth 22
Pune 22
Redmond 22
Verona 22
Totale 29.931
Nome #
Carbamazepine-induced thrombocytopenic purpura in a child: Insights from a genomic analysis 533
5-Aminoimidazole-4-carboxamide ribonucleotide-transformylase and inosine-triphosphate-pyrophosphatase genes variants predict remission rate during methotrexate therapy in patients with juvenile idiopathic arthritis 500
Azathioprine Biotransformation in Young Patients with Inflammatory Bowel Disease: Contribution of Glutathione-S Transferase M1 and A1 Variants 497
Long Noncoding RNA GAS5: A Novel Marker Involved in Glucocorticoid Response 470
Glucocorticoid pharmacogenetics in pediatric idiopathic nephrotic syndrome 463
Role of Oxidative Stress Mediated by Glutathione-S-transferase in Thiopurines' Toxic Effects 450
Pharmacogenetics of thiopurines 447
Role of Pharmacogenetics in Hematopoietic Stem Cell Transplantation Outcome in Children 424
Thiopurine metabolites variations during co-treatment with aminosalicylates for inflammatory bowel disease: Effect of N-acetyl transferase polymorphisms 421
Genetic determinants for methotrexate response in juvenile idiopathic arthritis 410
High-throughput sequencing of microRNAs in glucocorticoid sensitive paediatric inflammatory bowel disease patients 409
Patients' Induced Pluripotent Stem Cells to Model Drug Induced Adverse Events: A Role in Predicting Thiopurine Induced Pancreatitis? 389
Failure of interferon-γ pre-treated mesenchymal stem cell treatment in a patient with crohn's disease 379
Pharmacogenetics of treatments for inflammatory bowel disease 353
Therapeutic drug monitoring to improve outcome of anti-TNF drugs in pediatric inflammatory bowel disease 318
In vitro sensitivity to methyl-prednisolone is associated with clinical response in pediatric idiopathic nephrotic syndrome 314
Expression Pattern of Long Non-Coding RNA Growth Arrest-Specific 5 in the Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia 304
Role of the Long Non-Coding RNA Growth Arrest-Specific 5 in Glucocorticoid Response in Children with Inflammatory Bowel Disease 298
Endoscopic and Histologic Healing in Children With Inflammatory Bowel Diseases Treated With Thalidomide 290
Association of BclI polymorphism of the glucocorticoid receptor gene locus with response to glucocorticoids in inflammatory bowel disease. 282
Action of methotrexate and tofacitinib on directly stimulated and bystander-activated lymphocytes 281
Fate of Lymphocytes after Withdrawal of Tofacitinib Treatment 280
Pharmacotranscriptomic Biomarkers in Glucocorticoid Treatment of Pediatric Inflammatory Bowel Disease 279
Cytofluorimetric assay to investigate variability in blinatumomab in vitro response 279
The farnesyltransferase inhibitors tipifarnib and lonafarnib inhibit cytokines secretion in a cellular model of mevalonate kinase deficiency. 271
Causes of Treatment Failure in Children With Inflammatory Bowel Disease Treated With Infliximab: A Pharmacokinetic Study 270
Cancer Pharmacogenetics: perspective on newly discovered and implemented predictive biomarkers 270
Glucocorticoid Receptor Interacting Co-regulators: Putative Candidates for Future Drug Targeting Therapy 265
Contribution of Glutathione-S-Transferases to the Pharmacogenetics of Azathioprine 264
Decreased cholesterol levels reflect a consumption of anti-inflammatory isoprenoids associated with an impaired control of inflammation in a mouse model of mevalonate kinase deficiency. 263
Thymidilate synthase expression predicts longer survival in patients with stage II colon cancer treated with 5-flurouracil independently of microsatellite instability 262
Ergothioneine, a dietary amino acid with a high relevance for the interpretation of label-free surface enhanced Raman scattering (SERS) spectra of many biological samples 261
Epratuzumab and Blinatumomab as Therapeutic Antibodies for Treatment of Pediatric Acute Lymphoblastic Leukemia: Current Status and Future Perspectives 261
Differential action of 3-hydroxyanthranilic acid on viability and activation of stimulated lymphocytes. 259
Induced pluripotent stem cells for therapy personalization in pediatric patients: Focus on drug-induced adverse events 259
Effect of thalidomide on clinical remission in children and adolescents with ulcerative colitis refractory to other immunosuppressives: Pilot randomized clinical trial 256
Generation of 3 clones of induced pluripotent stem cells (iPSCs) from a patient affected by Crohn's disease 255
PACSIN2 rs2413739 influence on thiopurine pharmacokinetics: validation studies in pediatric patients 254
Amelioration of 4'-Epidoxorubicin-induced cardiotoxicity by sodium cromoglycate. 252
Deletion of Glutathione-S-Transferase M1 Reduces Azathioprine Metabolite Concentrations in Young Patients With Inflammatory Bowel Disease. 252
Targeting kinase-activating genetic lesions to improve therapy of pediatric acute lymphoblastic leukemia 248
Multicentric Case-Control Study on Azathioprine Dose and Pharmacokinetics in Early-onset Pediatric Inflammatory Bowel Disease 247
Induction of proteins involved in multidrug resistance (P-glycoprotein, MRP1, MRP2, LRP) and of CYP 3A4 by rifampicin in LLC-PK1 cells. 246
Determination of Serum Infliximab Concentration by Point-of-care Devices in Children with Inflammatory Bowel Disease 246
Long non-coding RNA gas5 and intestinal mmp2 and mmp9 expression: A translational study in pediatric patients with IBD 245
Novel motif of variable number of tandem repeats in TPMT promoter region and evolutionary association of variable number of tandem repeats with TPMT∗3 alleles 243
Hemolytic Effects of Water-Soluble Fullerene Derivatives 242
Opioid Resistance Associated with CYP3A4 Hyperactivity and COMT Polymorphism in an Oncological Patient 242
Carbamazepine hypersensitivity syndrome triggered by a human herpes virus reactivation in a genetically predisposed patient 241
Association between BclI polymorphism in the NR3C1 gene and in vitro individual variations in lymphocyte responses to methylprednisolone. 240
Interruption of mesalamine and reduction of the blood concentration of the active metabolites of azathioprine: possible causes of ulcerative colitis relapse. 237
Risk Factors and Outcomes of Thalidomide-induced Peripheral Neuropathy in a Pediatric Inflammatory Bowel Disease Cohort 230
MicroRNAs as tools to predict glucocorticoid response in inflammatory bowel diseases. 228
Emerging Insights on the Interaction Between Anticancer and Immunosuppressant Drugs and Intestinal Microbiota in Pediatric Patients 228
Glutathione-S-Transferase-P1 I105V polymorphism and response to antenatal betamethasone in the prevention of respiratory distress syndrome 227
Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol 227
Anticonvulsant activity of two polyethylene glycols in mice. 226
Pharmacogenetics of azathioprine in inflammatory bowel disease: A role for glutathione-S-transferase? 225
Pharmacokinetics and pharmacodynamics of thiopurines in an in vitro model of human hepatocytes: Insights from an innovative mass spectrometry assay 225
The cytotoxic effect of palytoxin on Caco-2 cells hinders their use for in vitro absorption studies. 224
Pharmacogenetic determinants of response to infliximab in pediatric inflammatory bowel disease 224
Targeting farnesyl-transferase as a novel therapeutic strategy for mevalonate kinase deficiency: In vitro and in vivo approaches. 222
Rifampicin and verapamil induce the expression of P-glycoprotein in vivo in Ehrlich ascites tumor cells. 221
Pharmacogenomic approaches for tailored anti-leukemic therapy in children. 221
Antibiotics and Liver Cirrhosis: What the Physicians Need to Know 221
Natural isoprenoids are able to reduce inflammation in a mouse model of mevalonate kinase deficiency. 220
Glutathione-S-transferase genotypes and the adverse effects of azathioprine in young patients with inflammatory bowel disease 218
Adriamycin binds to the matrix of secretory granules during mast cell exocytosis. 218
Biochemical and microscopic evidence for the internalization of drug-containing mast cell granules by macrophages and smooth muscle cells 216
Oxidative stress-based cytotoxicity of delphinidin and cyanidin in colon cancer cells. 216
Physiological regulation of P-glycoprotein, MRP1, MRP2 and cytochrome P450 3A2 during rat ontogeny. 216
Imidazo[2,1-b]benzothiazol derivatives as potential allosteric inhibitors of the glucocorticoid receptor 216
Understanding thiopurine methyltransferase polymorphisms for the targeted treatment of hematologic malignancies 216
ABCB1 gene polymorphisms and expression of P-glycoprotein and long term prognosis in colorectal cancer 214
Effect of neomycin and other aminoglycosides on adriamycin uptake in rat peritoneal mast cells. 214
SERS of cells: What can we learn from cell lysates? 213
Glucocorticoids in Pediatric Gastrointestinal Disorders 211
Effect of ketotifen on adriamycin toxicity: role of histamine. 208
Response to glucocorticoids and toxicity in childhood acute lymphoblastic leukemia: role of polymorphisms of genes involved in glucocorticoid response. 207
Molecular mechanism of glucocorticoid resistance in inflammatory bowel disease. 207
Genetic Predictors of Glucocorticoid Response in Pediatric Patients With Inflammatory Bowel Diseases 205
Effect of periodontal therapy on the course of cyclosporin-induced gingival overgrowth: role of ABCB1 and PAI-1 gene polymorphisms. 205
Glutathione S-Transferase homozygous deletions and relapse in childhood acute lymphoblastic leukemia: a novel study design in a large Italian AIEOP cohort. 204
Selective resistance to different glucocorticoids in severe autoimmune disorders 202
Osteonecrosis of the hip after short courses of oral and inhaled steroids in a child with an increased number of glucocorticoid receptors 201
Adriamycin-induced histamine release from heart tissue in vitro. 200
Visualization of adriamycin uptake and internalization by receptor-mediated endocytosis in mast cells. An ultrastructural study using adriamycin-colloidal gold complexes. 200
Prevalence of methylenetetrahydrofolate reductase polymorphisms in young patients with inflammatory bowel disease. 199
Personalized therapies in pediatric inflammatory and autoimmune diseases. 199
Extracellular Vesicles as Innovative Tools for Assessing Adverse Effects of Immunosuppressant Drugs 199
Letter: TPMT activity and age in IBD patients. 198
Cellular antioxidant activities and cytotoxic properties of ethanolic extracts of four tropical green leafy vegetables 198
Effects of antimetastatic, antiinvasive and cytotoxic agents on the growth and spread of transplantable leukemias in mice. 198
Differential expression of GAS5 in rapamycin-induced reversion of glucocorticoid resistance 197
Cytofluorimetric analysis of a renal tubular cell line and its resistant counterpart 195
TNF-α SNP rs1800629 and risk of relapse in childhood acute lymphoblastic leukemia: relation to immunophenotype 194
Usefulness of the measurement of azathioprine metabolites in the assessment of non-adherence 192
Adriamycin experimental cardiomyopathy in Swiss mice. Different effects of two calcium antagonistic drugs on ADM - induced cardiomyopathy. 192
Atomic Force Microscopy Application for the Measurement of Infliximab Concentration in Healthy Donors and Pediatric Patients with Inflammatory Bowel Disease 189
Characterization of histamine secretion induced by anthracyclines in rat peritoneal mast cells. 189
Totale 26.236
Categoria #
all - tutte 118.170
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 118.170


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021848 0 0 0 0 0 0 0 0 0 395 144 309
2021/20222.595 124 158 123 243 56 225 186 104 299 277 160 640
2022/20233.860 372 559 271 571 369 647 32 318 425 57 162 77
2023/20242.382 128 170 107 139 249 197 444 460 39 66 225 158
2024/20256.105 120 245 401 573 571 644 415 418 780 767 575 596
2025/202611.818 1.306 633 825 1.065 1.230 1.265 2.022 430 1.553 1.489 0 0
Totale 43.701